Multi-Institutional Phase II Clinical Study of Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer in East and Southeast Asia

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 3, 2010, Pages 751-757

  Kato, Shingo ^a   Ohno, Tatsuya ^b   Thephamongkhol, Kullathorn ^c   Chansilpa, Yaowalak ^c   Yuxing, Yang ^d   Beena Devi, C R ^e   Bustam, Anita Z ^f   Calaguas, Miriam J C ^g   de los Reyes, Rey H ^h   Cho, Chul Koo ⁱ   Dung, To Anh ^j   Supriana, Nana ^k   Mizuno, Hideyuki ^a   Nakano, Takashi ^l   Tsujii, Hirohiko ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b GUNMA UNIVERSITY HEAVY ION MEDICAL CENTER   (Japan)

^c MAHIDOL UNIVERSITY   (Thailand)

^d China   (China)

^e SARAWAK GENERAL HOSPITAL   (Malaysia)

^f UNIVERSITY OF MALAYA   (Malaysia)

^g ST LUKE S MEDICAL CENTER   (Philippines)

^h Jose R Reyes Memorial Medical Center   (Philippines)

ⁱ Korea Cancer Center Hospital   (South Korea)

^j National Cancer Institute   (Viet Nam)

^k CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^l GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Cervical cancer; chemoradiotherapy; developing country; high dose rate brachytherapy; international clinical study

Indexed keywords

ASIAN COUNTRIES; BRACHYTHERAPY; CERVICAL CANCERS; CHEMORADIOTHERAPY; CIS-PLATIN; CLINICAL STUDY; CONCURRENT CHEMORADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL TOXICITIES; HIGH DOSE RATE; HIGH-DOSE RATE BRACHYTHERAPY; LOCAL CONTROL; LOW DOSE RATE; OVERALL SURVIVAL RATES; PHASE II; SOUTHEAST ASIA; SQUAMOUS CELL CARCINOMA; TOTAL DOSE;

CHEMOTHERAPY; DEVELOPING COUNTRIES; ONCOLOGY; PLATINUM COMPOUNDS; SOCIETIES AND INSTITUTIONS; TOXICITY;

RADIOTHERAPY;

CISPLATIN; CREATININE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER DISEASE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; EXTERNAL BEAM RADIOTHERAPY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RECTUM DISEASE; SIDE EFFECT; SOUTHEAST ASIA; SURVIVAL RATE; UTERINE CERVIX CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIA; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; HUMANS; LEUKOPENIA; MIDDLE AGED; NEUTROPENIA; RADIOTHERAPY DOSAGE; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 77952573174     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.011     Document Type: Article

References (21)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 (1999) 827-841
2. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
3. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
4. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
5. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161
6. Peters III W.A., Liu P.Y., Barrett II R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
7. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet 358 (2001) 781-786
8. Lukka H., Hirte H., Fyles A., et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-A meta-analysis. Clin Oncol 14 (2002) 203-212
9. Toita T., Moromizato H., Ogawa K., et al. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 96 (2005) 665-700
10. Chen S.W., Liang J.A., Hung Y.C., et al. Concurrent weekly cisplatin plus external beam radiotherapy and high-dose rate brachytherapy for advanced cervical cancer: A control cohort comparison with radiation alone on treatment outcome and complications. Int J Radiat Oncol Biol Phys 66 (2006) 1370-1377
11. Lanciano R., Calkins A., Bundy B.N., et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: A Gynecologic Oncology Group study. J Clin Oncol 23 (2005) 8289-8295
12. th, 2009.
13. Nakano T., Kato S., Cao J., et al. A regional cooperative clinical study of radiotherapy for cervical cancer in east and southeast Asian countries. Radiother Oncol 84 (2007) 314-319
14. Ohno T., Nakano T., Kato S., et al. Accelerated hyperfractionated radiotherapy for cervical cancer: Multi-institutional prospective study of Forum for Nuclear Cooperation in Asia among eight Asian countries. Int J Radiat Oncol Biol Phys 70 (2008) 1522-1529
15. National Cancer Institute. Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE) (2003), National Cancer Institute, Bethesda
16. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiotherapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
17. Monk B.J., Tewari K.S., and Koh W.-J. Multimodality therapy for locally advanced cervical carcinoma: State of the art and future directions. J Clin Oncol 25 (2007) 2952-2965
18. Teshima T., Inoue T., Ikeda H., et al. High-dose rate and low-dose rate intracavitary therapy for carcinoma of the uterine cervix: Final results of Osaka University Hospital. Cancer 72 (1993) 2409-2414
19. Patel F.D., Sharma S.C., Negi P.S., et al. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: A clinical trial. Int J Radiat Oncol Biol Phys 28 (1994) 335-341
20. Nakano T., Kato S., Ohno T., et al. Long-term results of high-dose-rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 103 (2005) 92-101
21. Nag S., Chao C., Erickson B., et al. for the American Brachytherapy Society. The American Brachytherapy Society recommendations for low-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 52 (2002) 33-48